Selected Drugs Clear All
MultiCheck Results
- 34
Interactions
Avoid/Use Alternative |
||
|
famotidine
(generic) + ferrous sulfate
(generic) |
||
Avoid/Use Alternativefamotidine + ferrous sulfate use alternative or give iron 1h before: combo may decr. iron efficacy (absorption decreased at higher gastric pH) |
||
|
Frova
(frovatriptan) + kawa
(kava (Piper methysticum)) |
||
Avoid/Use Alternativefrovatriptan + kava avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Frova
(frovatriptan) + sodium oxybate
(generic) |
||
Avoid/Use Alternativefrovatriptan + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
kawa
(kava (Piper methysticum)) + lamotrigine
(generic) |
||
Avoid/Use Alternativekava + lamotrigine avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
kawa
(kava (Piper methysticum)) + Levsin
(hyoscyamine) |
||
Avoid/Use Alternativekava + hyoscyamine avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
kawa
(kava (Piper methysticum)) + Robaxin
(methocarbamol) |
||
Avoid/Use Alternativekava + methocarbamol avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
kawa
(kava (Piper methysticum)) + sodium oxybate
(generic) |
||
Avoid/Use Alternativekava + oxybate avoid combo: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
lamotrigine
(generic) + sodium oxybate
(generic) |
||
Avoid/Use Alternativelamotrigine + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Levsin
(hyoscyamine) + sodium oxybate
(generic) |
||
Avoid/Use Alternativehyoscyamine + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Robaxin
(methocarbamol) + sodium oxybate
(generic) |
||
Avoid/Use Alternativemethocarbamol + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
Monitor/Modify Tx |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + Exforge
(amlodipine/ valsartan) |
||
Monitor/Modify Txgalcanezumab + amlodipine monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) galcanezumab + valsartan monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + Frova
(frovatriptan) |
||
Monitor/Modify Txgalcanezumab + frovatriptan monitor BP: combo may incr. risk of HTN (additive effects) |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txgalcanezumab + licorice monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects) |
||
|
Exforge
(amlodipine/ valsartan) + Frova
(frovatriptan) |
||
Monitor/Modify Txamlodipine + frovatriptan monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) valsartan + frovatriptan monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Exforge
(amlodipine/ valsartan) + ginseng, Asian (Panax ginseng)
(common name) |
||
Monitor/Modify Txamlodipine + ginseng, Asian monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metab. induced) |
||
|
Exforge
(amlodipine/ valsartan) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txamlodipine + licorice monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects) valsartan + licorice monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Exforge
(amlodipine/ valsartan) + RhoGAM
(Rho(D) immune globulin) |
||
Monitor/Modify Txvalsartan + Rho(D) immune globulin monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects) |
||
|
Exforge
(amlodipine/ valsartan) + Urecholine
(bethanechol) |
||
Monitor/Modify Txamlodipine + bethanechol monitor BP: combo may incr. risk of hypotension (additive effects) valsartan + bethanechol monitor BP: combo may incr. risk of hypotension (additive effects) |
||
|
ferrous sulfate
(generic) + Levsin
(hyoscyamine) |
||
Monitor/Modify Txferrous sulfate + hyoscyamine separate admin. by 1h: combo may decr. hyoscyamine levels, efficacy (absorption decreased via chelation) |
||
|
Frova
(frovatriptan) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txfrovatriptan + licorice monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects) |
||
|
progesterone micronized
(generic) + RhoGAM
(Rho(D) immune globulin) |
||
Monitor/Modify Txprogesterone (hormone replacement) + Rho(D) immune globulin monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects) |
||
Caution Advised |
||
|
Frova
(frovatriptan) + lamotrigine
(generic) |
||
Caution Advisedfrovatriptan + lamotrigine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Frova
(frovatriptan) + Levsin
(hyoscyamine) |
||
Caution Advisedfrovatriptan + hyoscyamine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Frova
(frovatriptan) + Robaxin
(methocarbamol) |
||
Caution Advisedfrovatriptan + methocarbamol caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
lamivudine
(generic) + lamotrigine
(generic) |
||
Caution Advisedlamivudine + lamotrigine caution advised: combo may incr. lamivudine levels, risk of adverse effects (renal transport possibly inhibited) |
||
|
lamotrigine
(generic) + Levsin
(hyoscyamine) |
||
Caution Advisedlamotrigine + hyoscyamine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
lamotrigine
(generic) + Robaxin
(methocarbamol) |
||
Caution Advisedlamotrigine + methocarbamol caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, methocarbamol may decr. seizure threshold) |
||
|
Levsin
(hyoscyamine) + Robaxin
(methocarbamol) |
||
Caution Advisedhyoscyamine + methocarbamol caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
Levsin
(hyoscyamine) + Urecholine
(bethanechol) |
||
Caution Advisedhyoscyamine + bethanechol caution advised: combo may decr. efficacy of both drugs (antagonistic effects) |
||
|
Robaxin
(methocarbamol) + Urecholine
(bethanechol) |
||
Caution Advisedmethocarbamol + bethanechol caution advised: combo may decr. efficacy of both drugs (antagonistic effects) |
||
Additional Considerations |
||
|
amlodipine
in Exforge
|
||
|
levamlodipine is the active isomer of racemic amlodipine; similar interactions anticipated |
||
|
Saccharomyces boulardii
in Florastor
|
||
|
caution advised; combo w/ antifungals may decr. Saccharomyces boulardii efficacy |
||
|
nicotine
in Nicotrol NS
|
||
|
caution advised w/ concomitant drugs; dose adjustments may be necessary; smoking cessation may alter pharmacokinetics or pharmacodynamics of certain drugs |
||
|
lamotrigine
|
||
|
caution advised w/ other sodium channel blockers; combo may incr. risk of ECG changes, cardiac arrhythmias; additive effects |
||
|
hyoscyamine
in Levsin
|
||
|
caution advised w/ concurrent oral drugs requiring rapid onset; hyoscyamine delays gastric emptying, may alter absorption of concomitant oral drugs |
||
|
lamivudine
|
||
|
avoid combo of lamivudine oral solution w/ oral products containing sorbitol; may give lamivudine tab formulation or monitor virologic response more frequently if combo cannot be avoided; sorbitol may decr. bioavailability of lamivudine, resulting in decr. levels, efficacy |
||